Chengdu Huasun Group Inc Ltd Asset Resilience Ratio
Chengdu Huasun Group Inc Ltd asset resilience ratio. Chengdu Huasun Group Inc Ltd (000790) has an Asset Resilience Ratio of 0.31% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Chengdu Huasun Group Inc Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chengdu Huasun Group Inc Ltd (1995–2024)
Asset resilience ratio of Chengdu Huasun Group Inc Ltd from 1995 to 2024. This chart shows how Chengdu Huasun Group Inc Ltd's Asset Resilience Ratio has changed over time. See Chengdu Huasun Group Inc Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Chengdu Huasun Group Inc Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Chengdu Huasun Group Inc Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥6.56 Million | 0.31% |
| Total Liquid Assets | CN¥6.56 Million | 0.31% |
Asset Resilience Insights
- Limited Liquidity: Chengdu Huasun Group Inc Ltd maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chengdu Huasun Group Inc Ltd Industry Peers by Asset Resilience Ratio
Compare Chengdu Huasun Group Inc Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915 |
Drug Manufacturers - Specialty & Generic | 25.22% |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505 |
Drug Manufacturers - Specialty & Generic | 11.06% |
Chengdu Huasun Group Inc Ltd Asset Resilience Ratio by Year (1995–2024)
Chengdu Huasun Group Inc Ltd asset resilience ratio by year from 1995 to 2024. The table below shows the annual Asset Resilience Ratio data for Chengdu Huasun Group Inc Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.29% | CN¥6.56 Million ≈ $959.95K |
CN¥2.25 Billion ≈ $329.13 Million |
-1.66pp |
| 2020-12-31 | 1.95% | CN¥22.23 Million ≈ $3.25 Million |
CN¥1.14 Billion ≈ $166.82 Million |
-1.90pp |
| 1996-12-31 | 3.85% | CN¥7.11 Million ≈ $1.04 Million |
CN¥184.48 Million ≈ $27.00 Million |
-1.62pp |
| 1995-12-31 | 5.48% | CN¥8.64 Million ≈ $1.26 Million |
CN¥157.76 Million ≈ $23.09 Million |
-- |
About Chengdu Huasun Group Inc Ltd
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs; and medicines for the treatment of … Read more